Abstract
For patients with wild-type lung adenocarcinoma, the options for first-line therapy have significantly expanded in recent years. Improvements in combination chemotherapy, maintenance treatment, patient selection, and addition of antiangiogenic therapy have all modestly improved survival over the past decade. Immune checkpoint modulation with programmed death-1 (PD-1) inhibition has shown considerable promise in fundamentally changing the approach to patients with advanced lung adenocarcinoma. PD-1 inhibition is particularly promising as single agent therapy or in combination with chemotherapy depending on programmed death ligand 1 (PD-L1) expression. Future investigations are combining PD-1/L1 with chemotherapy and other immune-oncology agents in an effort to further improve efficacy.
Original language | English (US) |
---|---|
Title of host publication | Pulmonary Adenocarcinoma |
Subtitle of host publication | Approaches to Treatment |
Publisher | Elsevier |
Pages | 87-102 |
Number of pages | 16 |
ISBN (Electronic) | 9780323554336 |
DOIs | |
State | Published - Jan 1 2018 |
Keywords
- Adenocarcinoma
- Bevacizumab
- Chemotherapy
- First-line
- Immunotherapy
- Lung
ASJC Scopus subject areas
- General Medicine